开云app官网登录入口网页版-官方正版

#候选药物#

51篇内容 | 1724人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2052438, encodeId=c1ca20524380d, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=Nature子刊：通过实体瘤癌症患者来源的类器官，筛选到临床候选药物, objectType=article, longId=727560, objectId=d6e0e275605c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6e0e275605c, replyNumber=0, likeNumber=54, createdTime=2023-04-20, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6e0e275605c, moduleTitle=Nature子刊：通过实体瘤癌症患者来源的类器官，筛选到临床候选药物, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d6e0e275605c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052440, encodeId=e75520524408a, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=Nature子刊：乳腺癌候选药物，明年初将开展临床试验, objectType=article, longId=729639, objectId=6132e2963931, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6132e2963931, replyNumber=0, likeNumber=88, createdTime=2023-02-25, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6132e2963931, moduleTitle=Nature子刊：乳腺癌候选药物，明年初将开展临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6132e2963931)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052437, encodeId=4089205243e6c, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=Circulation：张岩/雷晓光合作发现治疗心脏损伤候选药物分子, objectType=article, longId=724368, objectId=68e8e2436817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68e8e2436817, replyNumber=0, likeNumber=85, createdTime=2022-12-22, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68e8e2436817, moduleTitle=Circulation：张岩/雷晓光合作发现治疗心脏损伤候选药物分子, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=68e8e2436817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052442, encodeId=97e5205244251, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=Nat Commun：新型候选药物或能利用新型吸收策略来靶向作用小鼠机体中的癌细胞, objectType=article, longId=736849, objectId=f583e3684951, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f583e3684951, replyNumber=0, likeNumber=102, createdTime=2022-09-22, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f583e3684951, moduleTitle=Nat Commun：新型候选药物或能利用新型吸收策略来靶向作用小鼠机体中的癌细胞, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f583e3684951)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052436, encodeId=7c5c20524367e, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=JMC：上海药物所南发俊、谢欣课题组合作发现新型抗溃疡性结肠炎候选药物, objectType=article, longId=299834, objectId=f7ee29983498, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7ee29983498, replyNumber=0, likeNumber=92, createdTime=2022-05-02, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7ee29983498, moduleTitle=JMC：上海药物所南发俊、谢欣课题组合作发现新型抗溃疡性结肠炎候选药物, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f7ee29983498)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052439, encodeId=1f1b205243982, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=Nature Cancer：世界首次，通过实体瘤癌症患者来源的类器官，筛选到临床候选药物, objectType=article, longId=727612, objectId=6164e27612cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6164e27612cb, replyNumber=0, likeNumber=85, createdTime=2022-12-16, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6164e27612cb, moduleTitle=Nature Cancer：世界首次，通过实体瘤癌症患者来源的类器官，筛选到临床候选药物, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6164e27612cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052441, encodeId=8221205244129, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=乳糜泻候选药物Larazotide 3期试验失败, objectType=article, longId=730267, objectId=02f7e30267b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02f7e30267b6, replyNumber=0, likeNumber=0, createdTime=2022-11-29, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02f7e30267b6, moduleTitle=乳糜泻候选药物Larazotide 3期试验失败, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=02f7e30267b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052432, encodeId=2de72052432bb, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=因明生物完成近5000万美元A+轮融资，加速重磅管线候选药物临床试验, objectType=article, longId=217044, objectId=c32221e04412, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c32221e04412, replyNumber=0, likeNumber=45, createdTime=2021-09-27, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c32221e04412, moduleTitle=因明生物完成近5000万美元A+轮融资，加速重磅管线候选药物临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c32221e04412)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052433, encodeId=51f1205243372, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=阿尔茨海默病候选药物ACD856，新一轮I期研究已经启动, objectType=article, longId=218127, objectId=6f2821812eb6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f2821812eb6, replyNumber=0, likeNumber=81, createdTime=2022-06-16, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f2821812eb6, moduleTitle=阿尔茨海默病候选药物ACD856，新一轮I期研究已经启动, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6f2821812eb6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052435, encodeId=6eef205243587, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=Nature：一次用药，长期保护，吉利德开发的艾滋病候选药物在灵长类动物中效果显著, objectType=article, longId=291796, objectId=1968291e9608, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1968291e9608, replyNumber=0, likeNumber=96, createdTime=2022-08-31, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1968291e9608, moduleTitle=Nature：一次用药，长期保护，吉利德开发的艾滋病候选药物在灵长类动物中效果显著, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1968291e9608)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052434, encodeId=2ac92052434d3, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=冠科生物推出“三维体外患者组织平台”，以提高对免疫肿瘤候选药物应答的可预测性, objectType=article, longId=218477, objectId=16ef2184e7b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16ef2184e7b7, replyNumber=0, likeNumber=68, createdTime=2022-03-14, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16ef2184e7b7, moduleTitle=冠科生物推出“三维体外患者组织平台”，以提高对免疫肿瘤候选药物应答的可预测性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=16ef2184e7b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052429, encodeId=52f42052429fc, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=如何治疗系统性硬化症？候选药物GS248或提供临床益处, objectType=article, longId=206374, objectId=e0082063e4e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0082063e4e6, replyNumber=0, likeNumber=68, createdTime=2021-10-23, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0082063e4e6, moduleTitle=如何治疗系统性硬化症？候选药物GS248或提供临床益处, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e0082063e4e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052430, encodeId=9acc205243082, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=甘李药业的候选药物GLR2007已获得美国FDA“快速通道资格”, objectType=article, longId=206508, objectId=b3e020650836, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3e020650836, replyNumber=0, likeNumber=79, createdTime=2021-03-03, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3e020650836, moduleTitle=甘李药业的候选药物GLR2007已获得美国FDA“快速通道资格”, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b3e020650836)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052431, encodeId=ed5a2052431de, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=结直肠癌候选药物RCC-33将小鼠肿瘤体积降低了27％, objectType=article, longId=206792, objectId=bc24206e92c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc24206e92c4, replyNumber=0, likeNumber=65, createdTime=2021-11-05, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc24206e92c4, moduleTitle=结直肠癌候选药物RCC-33将小鼠肿瘤体积降低了27％, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bc24206e92c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052428, encodeId=4af22052428b0, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=FDA批准候选药物lanifibranor进入III期临床，以治疗非酒精性脂肪性肝炎（NASH）, objectType=article, longId=203274, objectId=cfcb2032e4c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfcb2032e4c1, replyNumber=0, likeNumber=61, createdTime=2021-05-03, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfcb2032e4c1, moduleTitle=FDA批准候选药物lanifibranor进入III期临床，以治疗非酒精性脂肪性肝炎（NASH）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cfcb2032e4c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052426, encodeId=7eea205242645, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=抗COVID-19单克隆抗体候选药物CT-P59：I期临床试验获得积极结果, objectType=article, longId=200591, objectId=c78820059127, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c78820059127, replyNumber=0, likeNumber=69, createdTime=2021-07-19, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c78820059127, moduleTitle=抗COVID-19单克隆抗体候选药物CT-P59：I期临床试验获得积极结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c78820059127)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052427, encodeId=7c39205242e88, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=呼吸道合胞病毒（RSV）疫苗候选药物的I / II期试验：已取得阳性结果, objectType=article, longId=202408, objectId=fdbb20240807, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdbb20240807, replyNumber=0, likeNumber=78, createdTime=2021-01-31, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdbb20240807, moduleTitle=呼吸道合胞病毒（RSV）疫苗候选药物的I / II期试验：已取得阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fdbb20240807)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052422, encodeId=890c2052422b4, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=Int J Mol Sci：槲皮素可成为预防造影剂肾病的临床候选药物, objectType=article, longId=189223, objectId=19ae18922303, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19ae18922303, replyNumber=0, likeNumber=61, createdTime=2020-04-21, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19ae18922303, moduleTitle=Int J Mol Sci：槲皮素可成为预防造影剂肾病的临床候选药物, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=19ae18922303)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052425, encodeId=f040205242572, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=抗COVID-19候选药物Brilacidin具有抗SARS-CoV-2活性！即将进行临床试验, objectType=article, longId=199923, objectId=466b1999231b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=466b1999231b, replyNumber=0, likeNumber=82, createdTime=2020-12-03, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=466b1999231b, moduleTitle=抗COVID-19候选药物Brilacidin具有抗SARS-CoV-2活性！即将进行临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=466b1999231b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2052423, encodeId=25a22052423ac, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, objectTitle=Hanmi的NASH候选药物HM15211治疗硬化性胆管炎，获得FDA孤儿药称号, objectType=article, longId=189674, objectId=42571896e458, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42571896e458, replyNumber=0, likeNumber=90, createdTime=2020-03-31, rootId=0, userName=yuanming7, userId=467c360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42571896e458, moduleTitle=Hanmi的NASH候选药物HM15211治疗硬化性胆管炎，获得FDA孤儿药称号, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=42571896e458)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

候选药物

2020-05-29

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

Nature子刊：通过实体瘤癌症患者来源的类器官，筛选到临床候选药物

2023-04-20

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

Nature子刊：乳腺癌候选药物，明年初将开展临床试验

2023-02-25

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

Circulation：张岩/雷晓光合作发现治疗心脏损伤候选药物分子

2022-12-22

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

Nat Commun：新型候选药物或能利用新型吸收策略来靶向作用小鼠机体中的癌细胞

2022-09-22

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

JMC：上海药物所南发俊、谢欣课题组合作发现新型抗溃疡性结肠炎候选药物

2022-05-02

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

Nature Cancer：世界首次，通过实体瘤癌症患者来源的类器官，筛选到临床候选药物

2022-12-16

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

乳糜泻候选药物Larazotide 3期试验失败

2022-11-29

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

因明生物完成近5000万美元A+轮融资，加速重磅管线候选药物临床试验

2021-09-27

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

阿尔茨海默病候选药物ACD856，新一轮I期研究已经启动

2022-06-16

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

Nature：一次用药，长期保护，吉利德开发的艾滋病候选药物在灵长类动物中效果显著

2022-08-31

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

冠科生物推出“三维体外患者组织平台”，以提高对免疫肿瘤候选药物应答的可预测性

2022-03-14

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

如何治疗系统性硬化症？候选药物GS248或提供临床益处

2021-10-23

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

甘李药业的候选药物GLR2007已获得美国FDA“快速通道资格”

2021-03-03

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

结直肠癌候选药物RCC-33将小鼠肿瘤体积降低了27％

2021-11-05

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

FDA批准候选药物lanifibranor进入III期临床，以治疗非酒精性脂肪性肝炎（NASH）

2021-05-03

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

抗COVID-19单克隆抗体候选药物CT-P59：I期临床试验获得积极结果

2021-07-19

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

呼吸道合胞病毒（RSV）疫苗候选药物的I / II期试验：已取得阳性结果

2021-01-31

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

Int J Mol Sci：槲皮素可成为预防造影剂肾病的临床候选药物

2020-04-21

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

抗COVID-19候选药物Brilacidin具有抗SARS-CoV-2活性！即将进行临床试验

2020-12-03

yuanming7 (审核中...)

前往app查看评论内容

#候选药物#

Hanmi的NASH候选药物HM15211治疗硬化性胆管炎，获得FDA孤儿药称号

2020-03-31

科室
- - 订阅+
  - 更多科室
工具
服务